Sanofi results: Genzyme doesn't paper over cracks, as emerging markets top US and EU
This article was originally published in Scrip
Executive Summary
Sanofi reported 3% growth in sales in 2011, but with expiries of patents for major drugs still coming through, the company admitted that it a decline in profits would continue into 2012. This was despite the boost to sales provided by last year's acquisition of Genzyme.